| Outcome . | Patients (responders/all) . | Response rate (%) . | Range of response (%) . |
|---|---|---|---|
| Primary end pointa | 266/715 | 37.2 | 21.1–44.8 |
| SRI-4 | 160/371 | 43.1 | 33–48 |
| SRI-5 | 129/390 | 33.1 | 21–35.3 |
| SRI-6 | 155/490 | 31.6 | 19–34.6 |
| BICLA | 42/162 | 25.9 | 21.1–33 |
| Outcome . | Patients (responders/all) . | Response rate (%) . | Range of response (%) . |
|---|---|---|---|
| Primary end pointa | 266/715 | 37.2 | 21.1–44.8 |
| SRI-4 | 160/371 | 43.1 | 33–48 |
| SRI-5 | 129/390 | 33.1 | 21–35.3 |
| SRI-6 | 155/490 | 31.6 | 19–34.6 |
| BICLA | 42/162 | 25.9 | 21.1–33 |
aAs defined by each study
SRI-4: SLE Responder Index 4 (reduction of ≥4 in SELENA-SLEDAI or SLEDAI-2K, no worsening in PGA, no new A or two new B scores in the British Isles Lupus Assessment Group, BILAG)
SRI-5: as above with ≥5 reduction in SELENA-SLEDAI or SLEDAI-2K
SRI-6: as above with ≥6 reduction in SELENA-SLEDAI or SLEDAI-2K
BICLA: (BILAG-based Combined Lupus Assessment) improvement from baseline in the BILAG-2004 score, no worsening in SLEDAI-2K and PGA, no unpermitted changes in concomitant medications.
| Outcome . | Patients (responders/all) . | Response rate (%) . | Range of response (%) . |
|---|---|---|---|
| Primary end pointa | 266/715 | 37.2 | 21.1–44.8 |
| SRI-4 | 160/371 | 43.1 | 33–48 |
| SRI-5 | 129/390 | 33.1 | 21–35.3 |
| SRI-6 | 155/490 | 31.6 | 19–34.6 |
| BICLA | 42/162 | 25.9 | 21.1–33 |
| Outcome . | Patients (responders/all) . | Response rate (%) . | Range of response (%) . |
|---|---|---|---|
| Primary end pointa | 266/715 | 37.2 | 21.1–44.8 |
| SRI-4 | 160/371 | 43.1 | 33–48 |
| SRI-5 | 129/390 | 33.1 | 21–35.3 |
| SRI-6 | 155/490 | 31.6 | 19–34.6 |
| BICLA | 42/162 | 25.9 | 21.1–33 |
aAs defined by each study
SRI-4: SLE Responder Index 4 (reduction of ≥4 in SELENA-SLEDAI or SLEDAI-2K, no worsening in PGA, no new A or two new B scores in the British Isles Lupus Assessment Group, BILAG)
SRI-5: as above with ≥5 reduction in SELENA-SLEDAI or SLEDAI-2K
SRI-6: as above with ≥6 reduction in SELENA-SLEDAI or SLEDAI-2K
BICLA: (BILAG-based Combined Lupus Assessment) improvement from baseline in the BILAG-2004 score, no worsening in SLEDAI-2K and PGA, no unpermitted changes in concomitant medications.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
